Summary
Eli Lilly and Company (LLY) held its 2024 Annual Meeting of Shareholders on May 6, 2024, where a significant majority of outstanding shares (approximately 90%) were represented. The meeting's primary outcome was the election of four director nominees to three-year terms, with overwhelming support from shareholders. Additionally, shareholders advisory approved the compensation of the Company's named executive officers and ratified the appointment of Ernst & Young LLP as the independent auditor for 2024. However, two key governance proposals seeking to eliminate the classified board structure and supermajority voting provisions did not receive the required 80% of outstanding shares to pass. Several shareholder proposals regarding lobbying activities, diversity and inclusion effectiveness, the impact of patent exclusivities on product access, and the adoption of a comprehensive human rights policy also failed to gain majority approval. These voting outcomes indicate shareholder confidence in the current board and executive compensation, while also signaling a preference to maintain existing governance structures and a lack of consensus on specific governance and social responsibility initiatives presented.
Key Highlights
- 1All four nominated directors were overwhelmingly elected to serve three-year terms.
- 2Shareholders provided advisory approval for the compensation of the Company's named executive officers.
- 3The appointment of Ernst & Young LLP as the independent auditor for 2024 was ratified with strong shareholder support.
- 4A proposal to eliminate the classified board structure did not pass, requiring 80% of outstanding shares.
- 5A proposal to eliminate supermajority voting provisions also failed to meet the 80% outstanding shares threshold.
- 6Shareholder proposals related to lobbying activities, DEI effectiveness, patent exclusivity impact on access, and human rights policy were not approved.